Investigations in paediatric SLE contributed significantly to the discovery of the association of type I IFNs with lupus and underscored the potential application of this knowledge by informing the use of glucocorticoid therapy. Recent, promising research reveals biomarkers that may yield more focused clinical monitoring and assessment of response to treatment. This article reviews unique features of paediatric SLE and details important developments in paediatric lupus research.
Introduction
Recognition of the role of the innate immune system in the pathogenesis of SLE has resulted in a critical paradigm shift in our understanding of this potentially devastating disease. Groundbreaking research in paediatric lupus patients led to one of the first reports associating type I IFNs with lupus [1] . An extension of this work subsequently provided a rationale for care at the bedside guiding the use of glucocorticoids (GCs), the most commonly prescribed medication in the treatment of lupus [2] . Now, with the emergence of powerful technologies, including transcriptomics and proteomics, there is more in-depth study to further delineate disease pathogenesis and a considerable upsurge in the identification of novel biomarkers. Promising research in biomarker discovery may allow for more focused monitoring of a patient's clinical course and response to treatment in the future. In this review we highlight the unique features of paediatric SLE (pSLE) and summarize key advances from paediatric lupus research.
Approximately 20% of all patients with lupus are diagnosed in childhood before the age of 18 years [3] . Multiple studies comparing the clinical features of cohorts of adult and paediatric lupus highlight that children commonly manifest major organ involvement and more frequently accrue damage than adults [4] (Table 1) . A comparison of adult and pSLE found higher SLEDAI scores at presentation in children compared with adults and increased renal disease activity over time [5] . The estimated prevalence of nephritis ranges from 50 to 67% in pSLE cohorts compared with 3448% in adult cohorts [4] . Other clinical features differ, with haemolytic anaemia and malar rash being more common in children while discoid rash is more common in adults [6] . A meta-analysis of 16 studies detailing clinical differences between children and adults reported fever, lymphadenopathy, malar rash, ulcers, renal disease, seizures, haemolytic anaemia and thrombocytopenia were more common in children [7] . The comparison of clinical manifestations is presented in Table 1 [7] .
Prior studies have described the racial/ethnic disparities of SLE. In the large multi-ethnic adult SLE cohort of Lupus in Minority Populations: Nature vs Nurture, Hispanic and African American patients were found to have greater disease activity at an earlier age of onset compared with Caucasians [8] . Similarly, pSLE is also more severe in nonwhite populations. In a large cohort of 213 subjects with pSLE from Canada, renal disease was more common in Asians and subjects of African descent [9] . Even though the specific disease activity and damage measures did not vary by ethnic groups, the study revealed clinical heterogeneity within this multi-ethnic cohort [9] .
A recent large study of >40 000 adult SLE subjects from Medicaid data found significant differences in mortality rates by race and ethnicity. [10] . The standardized mortality ratio for SLE overall is estimated at 2.4 (95% CI 2.3, 2.5) but, in contrast, is strikingly high in adolescents and young [12] . Nineteen per cent of subjects were on dialysis and 12% had renal transplantation. Sixtyeight per cent were on GCs during study follow-up and 24% had disease flare within 3 months of follow-up [13] . Their findings suggest patients with pSLE continue to have severe disease in adulthood. In addition to this severe disease phenotype, children and adolescents are uniquely vulnerable to the long-term impacts of the disease. Ongoing exposure to chronic inflammation and toxic medication has the potential for multiple adverse effects. More than 90% of paediatric SLE patients receive GCs as a major component of their treatment [14] . In one large academic centre, 97% of childhood-onset SLE required GCs compared with 70% of adult-onset patients [5] . Consequently, children are commonly exposed not only to the typical significant adverse effects associated with GC use, such as weight gain and diabetes, but additionally have a singular risk of growth failure. Immunosuppressants, such as CYC, have cumulative toxicity, including increased risk of infertility and malignancy. Belimumab, the most recently approved SLE therapy by the US Food and Drug Administration, is now being evaluated for use in children in a clinical trial (ClinicalTrials.gov; NCT01649765). Belimumab exemplifies a more targeted therapy as a human IgG1-monoclonal antibody that binds to soluble human B lymphocyte stimulator and blocks the inhibition of B cell apoptosis and the stimulation of B cell differentiation into plasma cells. While it significantly decreased disease flare and reduced GC dose in clinical trials, patients with some of the most severe manifestations of SLE, including nephritis, were excluded from the study [15] . In addition to the trial in children, an active clinical trial of belimumab in LN (ClinicalTrials.gov; NCT01639339) may provide useful results. Although belimumab may be a promising new treatment, the severity of the illness in the paediatric population and chronic long-term exposure to the disease and its current therapies highlights the urgent need to gain a better understanding of disease pathogenesis for early diagnosis and intervention with more effective and targeted therapy to reduce the long-term burden of this potentially devastating chronic illness.
In our centre, patients with pSLE have been followed in a longitudinal translational study that highlighted the role of the innate immune system in disease pathogenesis and has translated to a more in-depth understanding of the impact of standard therapy [2] . We determined that peripheral blood mononuclear cells overexpress IFNregulated genes in almost 90% of active paediatric lupus patients [1] . Using microarray, the gene expression of 30 subjects with SLE was compared with JIA patients and healthy controls. The SLE subjects were clinically diverse and had a range of disease activity, with SLEDAI scores ranging from 0 to 20. Thirty per cent were newly diagnosed and the majority of subjects (80%) were being treated with steroids. Despite the clinical heterogeneity, the pSLE cohort displayed a strikingly homogeneous pattern of gene expression with upregulation of IFNassociated genes, termed the IFN-a signature. Further research revealed plasmacytoid dendritic cells (pDCs) are the primary producers of type I IFNs in SLE [16] . Although these findings were initially met with some scepticism, the IFN signature of SLE has been subsequently validated in paediatric and adult cohorts, though occurring less frequently in adult SLE (6080%) [17, 18] .
More recently, the dysregulation in IFN production and signalling has been highlighted as a critical pathway in a group of autoinflammatory diseases, commonly referred to as the monogenic interferonopathies, detailed in a recent review [19] . This group of diseases includes stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI), chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) and AicardiGoutieres syndrome (AGS). These diseases are characterized by upregulation of type I IFNs and share some of the typical manifestations of lupus but exhibit clinical phenotypes that are unique and distinct [19, 20] . While there are some common clinical phenotypes, including neurologic disease and skin manifestations, disease in other organs is variable. In addition, there are variable genetic mutations, sometimes with differential expression. Patients with interferonopathies typically develop clinical symptoms in early infancy. In SAVI, patients may develop severe vasculitis/vasculopathy and progressive interstitial lung disease due to a gain-offunction mutation in TMEM173 [21] . Patients develop joint contractures, myositis, neutrophilic dermatosis and lipodystrophy in CANDLE due to mutations in PSMB8 [19, 22] . In AGS, patients may have encephalomyelitis and rashes, including chilblains. Mutations in TREX1 cause some forms of AGS and familial chilblain lupus [23, 24] . Other mutations in TREX1 have been identified in patients with SLE and SS [24] .
An assessment of 20 AGS patients demonstrated clinical features of SLE that had not be described previously, including oral ulcers, arthritis and autoantibodies, in more than half (60%) of the cohort. They also reported the cooccurrence of SLE and AGS in two patients [25] . Their findings suggest an additional link between AGS and SLE beyond the established genetic mutations. While upregulation of IFN is common among the interferonopathies and SLE, the specific mechanism by which IFN may result in disease is variable and not fully understood. Furthermore, dysregulation of the adaptive immune system, critical to SLE pathogenesis, and the contribution of an environmental exposure do not appear to play an important role in the interferonopathies. As such, these differences may explain why these patients do not go on to develop SLE. Further understanding of these experiments is needed and will allow for a more comprehensive understanding of the molecular pathways associated with type I IFNs and ultimately may identify more specific therapeutic targets in the treatment of i26 www.rheumatology.oxfordjournals.org Tracey B. Wright and Marilynn Punaro SLE. One promising target is the inhibition of Janus kinases (JAKs), which result in the blockage of a positive feedback loop where by type I IFN production is increased through the upregulation of IFN-associated genes [21] . In SAVI, treatment with JAK inhibitors halted the transcription of a specific IFN gene, IFNB1, by 3050% and the induction of IFN response genes by 6090%. As a result, a JAK inhibitor, baricitinib (ClinicalTrials.gov; NCT01724580) is being studied for compassionate use in CANDLE and SAVI. In addition, the JAK inhibitor, tofacitinib, is currently under study in a clinical trial for SLE (ClinicalTrials.gov; NCT02535689).
Not only has discovery of the importance of the IFN pathway increased our understanding of SLE pathogenesis, it has also shown clinical relevance. The initial report of the IFN signature in pSLE demonstrated the downregulation of the IFN signature after an i.v. methylprednisolone (IVMP) pulse in three subjects [1] . Subsequent experiments demonstrated IVMP therapy consistently abrogates the IFN gene signature characteristic of active pSLE and decreases the pDCs, which produce IFN [2] . Gene expression was compared in pSLE in 30 untreated subjects, 6 subjects receiving pulse IVMP, 29 subjects receiving daily oral GCs of 510 mg and 6 subjects receiving daily oral GCs of 2030 mg. At day 1 post-pulse there was a significant reduction in the expression of IFNinducible genes. This reduction did not occur with the conventional doses of daily oral GCs. However, by day 8 the IFN gene signature was back to pre-pulse levels, a time correlating with regeneration of the pDC population (Fig. 1) . The ligation of toll-like receptor 7 (TLR7) and TLR9 by self-nucleic acidassociated immune complexes causes the pDCs to be relatively resistant to GCs. However, IVMP pulses, at high doses, overcome this resistance by killing the pDCs, thus transiently extinguishing the IFN signature until the pDC population repopulates in 1 week [2] .
This evidence suggests higher doses of intermittent IVMP may have a biologic rational in the treatment of pSLE. Even so, the use of GCs in therapy for SLE remains empiric. There are no evidence-based guidelines to establish the best use of GCs in pSLE as a standard of care. Prescribing patterns vary greatly by paediatric rheumatology centres [14] . The development of consensus treatment plans for induction therapy of proliferative nephritis through the Childhood Arthritis and Rheumatology Research Alliance represents a critical step to limit the variation in clinical practice among paediatric rheumatologists who care for SLE [26] . One of the GC regimens in these plans uses recurrent IVMP and was fashioned from the evidence generated from these gene expression studies. In the future, these plans will be evaluated through comparative effectiveness research to further inform the body of evidence needed to guide the choice of therapy in pSLE. Investigation of the adverse effects of therapy is also planned and is critically important to define the impact of recurrent IVMP in pSLE. Indeed, the adverse effects of high-dose GCs, including pulse IVMP, remain an important concern, but few studies in pSLE exist. In a large cohort of children with rheumatic disease, including pSLE, receiving intermittent IVMP, 22% experienced some adverse event, but the range of reactions was highly variable [27] . Behaviour changes, including mood lability, hallucinations, hyperactivity and sleep disturbances, were most common [27] .
In adult SLE, there is a similar need for robust clinical and biological evidence to support therapy decisions. The ACR's published guidelines for the management of SLE recommend pulse IVMP followed by daily oral GC (0.51 mg/kg/day), which is tapered to the least amount necessary for disease control, used in conjunction with immunosuppressant therapy [28] . The authors acknowledge the lack of data-driven evidence to determine an appropriate maintenance GC dose [28] . The impact of www.rheumatology.oxfordjournals.org i27 SLE and translational paediatric research low-to medium-dose GC (<30 mg/day) vs high-dose GC (>30 mg/day) was evaluated in a small SLE cohort, matched by sex and SLEDAI score. Both groups demonstrated a similar reduction in disease activity, but those receiving high-dose GCs were more likely to develop damage [29] . The effects of pulse IVMP are better defined in adults. In a study from the Hopkins Lupus Cohort, pulse IVMP was associated with chronic cognitive dysfunction and there was a trend towards an association with osteoporotic fractures [30] . This study highlighted the significant association between cumulative prednisone dose and several manifestations of damage, including cataracts, coronary artery disease and osteoporotic fractures [30] . In a cohort of 87 adults with SLE, i.v. steroids use was an independent risk factor for infection [31] . However, to our knowledge, no study in adult SLE has evaluated the specific impact of different GC dosing regimens on the IFN signature, further emphasizing the critical need for future mechanistic studies.
Beyond providing insight into the possible administration of current treatments such as GCs, the IFN signature itself is now being evaluated as a potential therapeutic target. There are three mAbs, sifalimumab, rontalizumab and Ags-009, which block IFN-a, and one mAb, anifrolumab, which blocks the IFN receptor currently under study [32] . Sifalimumab is a fully human monoclonal antibody with a satisfactory safety profile assessed for adult SLE patients with moderate to severe disease in phase 1 and 2 studies [33, 34] . In a multicentre, doubleblind, randomized clinical trial, subjects with moderate to severe SLE received sifalimumab at varying doses vs placebo [35] . In addition to evaluation of the safety and tolerability of sifalimumab, type I IFNinducible genes were also measured. Subjects with a high type I IFN signature demonstrated a greater decrease in disease activity compared with placebo, even after adjustment for the use of steroid bursts. The type I IFN signature was not completely suppressed, however, and it was speculated that other type I IFNs may be contributing to the signature [35] .
Rontalizumab is a humanized IgG1 monoclonal antibody directed against IFN-a that has been studied in phase 1 and 2 clinical trials [36, 37] . In the phase 1 clinical trial, adults with mildly active disease received rontalizumab and the expression of IFN-inducible genes and serum proteins were measured to determine the impact on the IFN signature. The phase 1 trial demonstrated an acceptable safety profile. The expression of IFN-inducible genes was decreased, but there was no change in IFN-induced serum proteins [36] . In the phase 2 trial in moderate to severe SLE, rontalizumb was compared with placebo in subjects receiving concurrent treatment with GCs and HCQ. There was no difference in disease activity. Subjects with a low IFN signature had a significantly greater response by the SLE response index compared with placebo. Because there was no difference in subjects with a high IFN signature, these results raise the question of whether there is sufficient suppression of the IFN gene signature.
Anifrolumab is a fully humanized mAb directed against subunit 1 of the type I IFN receptor. In a phase 2 trial of moderate to severe SLE, anifrolumab was compared with placebo, resulting in a significant reduction in disease activity using multiple measures of disease activity. The majority (75%) of the cohort had a high IFN signature and the effects of anifrolumab were pronounced in this subgroup [38] .
While the therapies targeting IFN-a have an adequate short-term safety profile, the extent to which IFN gene expression is suppressed differs among these treatments. Because type I IFN overexpression is almost universal in active pSLE, children and adolescents may be an excellent population to evaluate the impact of these promising therapies.
Although the discovery of the preeminent importance of type I IFNs in SLE has advanced our understanding, many questions still remain. In fact, gene expression of IFN-a has not proved to be a simple measure of disease activity, nor has this signature explained the clinical heterogeneity of patients in regard to disease manifestations and response to medications. Numerous advances in biomarker discovery have now focused on other markers, beyond IFN-a that may improve diagnostic and monitoring capabilities. Such biomarkers are urgently needed in both clinical trials and clinical care. In pSLE, most of these efforts have focused on LN, one of the most common clinical manifestations associated with significant morbidity. Neutrophil gelatinaseassociated lipocalin (NGAL) exemplifies one such promising biomarker that may improve the ability to monitor LN over time. NGAL is a glycosylated protein produced by many cells, including epithelial cells and neutrophils, and is upregulated in kidney injury [39] . In cross-sectional studies in pSLE, urine NGAL was associated with renal disease activity and was significantly higher in pSLE with nephritis compared with healthy controls or pSLE without nephritis [39] . In a longitudinal cohort of pSLE, urine NGAL increased 36 months prior to clinical worsening of renal disease. In addition, plasma NGAL increased significantly prior to clinical worsening of renal disease and 36 months prior to disease flare [40] . These findings support the potential utility of NGAL as a predictive biomarker. In conjunction with other urinary biomarkers, changes in NGAL were also associated with histological features of chronicity on renal biopsy [41] .
A recent study described the use of autoantigen microarrays to delineate multiple autoantibodies in pSLE [42] . In an analysis of 70 subjects with pSLE compared with healthy controls, they detected both well-described and novel autoantibodies. Of great interest was the discovery of the B cell activating factor (BAFF) autoantigen in pSLE, which had been previously described in adult SLE [43] . Furthermore, BAFF autoantibodies were associated with increased disease activity in pSLE. These findings may have implication in the use of BAFF inhibition in the treatment of pSLE. This group also identified novel autoantibodies associated with proliferative nephritis. The anti-C1q and anti-dsDNA autoantibodies and six other i28 www.rheumatology.oxfordjournals.org Tracey B. Wright and Marilynn Punaro clinical parameters were incorporated into a nephritis score that accurately identified 91% of the pSLE subjects as having proliferative nephritis (Fig. 2) . In a small subset of the cohort followed longitudinally, the nephritis score was elevated in subjects with proliferative nephritis even before the renal biopsies were obtained. These nephritis scores may also provide an opportunity to improve the ability to diagnose and follow patients over time.
Over the past decade, research in paediatric SLE has driven major advances in our understanding of lupus pathogenesis. Discovery of the IFN-a signature in SLE was a seminal event that highlighted the importance of innate immunity in this condition. Extension of this work has informed our understanding of the mechanisms driving GC resistance in SLE. Advances in biomarker discovery will yield more focused clinical monitoring and assessment of response to treatment in clinical trials. More in-depth analysis of longitudinal cohorts of pSLE is needed to illuminate the clinical and immunological heterogeneity of this disease and further inform the identification of novel biomarkers. The journey to elucidate the contributions of the innate immune system in SLE and expand the development and use of biomarkers is moving the field forward and will hopefully lead to more   FIG. 2 Identification of a paediatric SLE proliferative nephritis predictive signature (A) Least absolute shrinkage and selection operator (LASSO) was used on a training set of an ELISA and clinical measurements from 41 new-onset pSLE patient samples as a variable selection and linear regression to construct a predictive model of proliferative nephritis. A separate test set of 23 new-onset pSLE patient samples was used to evaluate the performance of the model. The nephritis scores obtained for each patient with the model are shown. Unfilled black circles indicate patients who were biopsied and found to be class II; unfilled black triangles indicate class V nephritis patients. The model was also used to calculate nephritis scores for samples from new-onset pSLE patients who were suspected to have nephritis but were not confirmed by biopsy (unknown). (B) Five pSLE patients from the test set were selected for longitudinal analysis. ELISA was used to determine each serum sample's anti-dsDNA and anti-C1q IgG levels and a chart review was performed to collect all applicable clinical data. The LASSO model based on the training set was used to calculate nephritis scores for each patient at each time point. Vertical dashed lines indicate when biopsies were performed and the horizontal dashed line indicates the nephritis score cut-off. Reprinted from Haddon DJ et al. Autoantigen microarrays reveal autoantibodies associated with proliferative nephritis and active disease in pediatric systemic lupus erythematosus. Arthritis Res Ther 17:162, ! 2015.
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